Theratechnologies Beta
What is the Beta of Theratechnologies?
The Beta of Theratechnologies, Inc. is 1.38
What is the definition of Beta?
BETA indicates whether a stock is more or less volatile than the market as a whole. A beta less than 1 indicates that the stock is less volatile than the market, while a beta more than 1 indicates that the stock is more volatile. Volatility is measured as the fluctuation of the price around the mean.
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
Beta of companies in the Health Care sector on TSX compared to Theratechnologies
What does Theratechnologies do?
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Companies with beta similar to Theratechnologies
- AXA SA has Beta of 1.38
- AXA SA has Beta of 1.38
- Freshii has Beta of 1.38
- Zai Lab has Beta of 1.38
- IFCI has Beta of 1.38
- IFCI has Beta of 1.38
- Theratechnologies has Beta of 1.38
- Beowulf Mining plc has Beta of 1.38
- Systemair AB (publ) has Beta of 1.38
- engage:BDR has Beta of 1.38
- Adtran has Beta of 1.38
- Abercrombie & Fitch Co has Beta of 1.38
- TruFin plc has Beta of 1.38